Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Hospital Safety-Net Burden and Outcomes of COVID-19 Hospitalizations in the US: Analysis of a National Multicenter Database
Olanipekun, Titilope , Chris-Olaiya, Abimbola , Siraw, Bekure , Isha, Shahin , Udongwo, Ndausung , Sanghavi, Devang , Chris-Olaiya, Abimbola , Shahin, Isha , Heaton, Joseph N. , Abe, Temidayo , Huespe, Iván

Journal of Intensive Care Medicine | August 11, 2025 | Volume: 41 | Issue: 4 | Pages: 336-343

10.1177/08850666251366167 | PMID 40785497 Get It

Background Safety-net hospitals (SNH) provide care to a significant proportion of low-income, uninsured, and underserved populations disproportionately affected by the COVID-19 pandemic. We evaluated the impact of safety-net burden on outcomes of COVID-19 hospitalizations. Methods We identified patients aged ≥ 18 years hospitalized with COVID-19 from the nationwide inpatient database using the International Classification of Diseases, Tenth Edition (ICD-10-CM) code U07.1. The primary study outcomes were inpatient mortality, respiratory failure requiring mechanical ventilation, and tracheostomy use. Secondary outcomes were total hospitalization costs (THC) and length of hospital stay (LOS). Multivariable logistic regression was used to compare the primary and secondary outcomes in HBH and medium safety-net burden (MBH) with lower-burden hospitals (LBH) (reference). Results An estimated 2,608,232 COVID-19 hospitalizations met the inclusion criteria, with 68.7% occurring in HBH, 22.8% in MBH, and 8.5% in LBH. On adjusted multivariable analysis, HBH was associated with increased odds of inpatient mortality (aOR 1.19, 95% CI 1.09-1.28) compared with LBH. Both HBH (aOR 1.30, 95% CI 1.21-1.40) and MBH (aOR 1.14, 95% CI 1.06-1.24) demonstrated increased odds of mechanical ventilation compared with LBH. THC was lower in HBH and MBH compared with LBH. The LOS was similar across safety net burden categories. Conclusion After adjusting for patient- and hospital-level factors, COVID-19 hospitalizations at HBH had inferior inpatient outcomes compared with LBH. Targeted policy reforms are needed to address the underlying causes of these disparities and increase our health systems’ readiness for future crises, particularly in underserved communities.
Updates on Recent Advancements in Hepatitis D Virus Treatment
Öztürk, Nazlı Begüm , Gürakar, Merve , Sequeira, Lynette M. , Yildiz, Elif , Özmert, Enis , Idılman, Ramazan , Gürakar, Ahmet , Ozturk, Nazli Begum , Gurakar, Merve , Sequeira, Lynette , Yildiz, Eda , Ozmert, Enis Hikmet , Idilman, Ramazan , Gurakar, Ahmet , Bardak, Ali Emre

Viruses | August 11, 2025 | Volume: 17 | Issue: 8 | Pages: 1100

10.3390/v17081100 | PMID 40872814 Get It

Hepatitis D virus (HDV) infection remains a major cause of severe liver disease among hepatitis B virus (HBV)-infected patients, contributing to accelerated progression to cirrhosis and hepatocellular carcinoma. Pegylated interferon-α remains the first-line therapy for chronic HDV infection in most cases. However, despite its approval for HBV and hepatitis C virus (HCV) infections, its use in HDV is largely driven by a lack of other options and is constrained by its limited efficacy, suboptimal durability of response, and a substantial side effect profile. Meanwhile, bulevirtide, an entry inhibitor, became the first agent to be approved for use in chronic HDV infections by the European Medicines Agency (EMA), and several other therapies are currently being investigated as well. In this review, we provide updates on recent advancements in HDV treatment and novel therapies.
Correction: de Almeida et al. The Challenges of Diagnosing, Managing, and Preventing Pediatric Delirium. Children 2025, 12, 918
Almeida, Juliana Patrícia Chaves de, Kawai, Yu , Prata‐Barbosa, Arnaldo , Kawai, Yu , Castro, Roberta Esteves Vieira de

Children | August 11, 2025 | Volume: 12 | Issue: 8 | Pages: 1050

10.3390/children12081050 | PMID 40868555 Get It

In the published publication [...]
Before It's Too Late: Recognizing the Impact of Seizures and Risk Factors for Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment
Feyissa, Anteneh M. , Feyissa, A M

Epilepsy Currents | August 11, 2025 | Volume: 25 | Issue: 6 | Pages: 392-394

10.1177/15357597251366616 | PMID 41798712 Get It

Association of Seizure Control with Mortality, Cognition, and Function in People With Dementia Zawar I, Quigg M, Ghosal S, Punia V, Calle-Lopez Y, Manning C, Kapur J. Ann Neurol . 2025;97(2):358–368. doi: 10.1002/ana.27125 . Epub 2024 Oct 30. PMID: 39475168 Objectives: The effects of seizure control on outcomes in persons with dementia (PWD) remain unclear. Our study aimed to investigate the impact of seizure control on mortality, function, cognition, and mood among PWD. Methods: This longitudinal, multicenter study is based on 39 Alzheimer's disease centers (ADCs) in the United States from September 2005 to December 2021. PWD were grouped by seizure status into recurrent (seizures in the past year), remote (prior seizures but none in the past year), and no seizures (controls). The primary outcome was all-cause mortality among seizure groups. We used Weibull survival analysis to assess the mortality risks by seizure status after adjusting for age, sex, education, race, ethnicity, hypertension, diabetes, hyperlipidemia, degree of cognitive impairment, dominant Alzheimer's disease (AD) mutation, brain trauma, stroke, Parkinson's disease, alcohol abuse, and depression. Cognition (Clinical Dementia Rating), function (physical dependence and nursing home residence), day-to-day activities (Functional Assessment Scores), and mood (Geriatric Depression Scale) were compared among seizure groups after adjusting for dementia duration and age. Results: Among 26,501 participants, 374 (1.4%) had recurrent seizures and 510 (1.9%) had remote seizures. In multivariable survival analysis, recurrent seizures were associated with a higher mortality risk than remote and no seizures (adjusted hazard ratio [aHR], 95% confidence interval [95% CI]; recurrent aHR = 1.79, 95% CI = 1.51 to 2.12; remote aHR = 1.17, 95%CI = 0.98 to 1.38). Median time-to-death for recurrent, remote, and no seizures was 2.4, 4.0, and 4.7 years, respectively. People with recurrent seizures had worse cognition, day-to-day function, and physical dependence than those with remote seizures and controls. Interpretation: PWD with poorly controlled recurrent seizures have worse mortality, functional, and cognitive outcomes than PWD with remote and no seizures. These findings underscore the need for timely identification and management of ongoing seizures in PWD. Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment Zawar I, Quigg M, Johnson EL, Ghosal S, Manning C, Kapur J. JAMA Neurol . 2025;82(6):605–613. doi: 10.1001/jamaneurol.2025.0552 . PMID: 40227723. Importance: The risk of developing epilepsy substantially increases after the age of 60 years (late-onset epilepsy [LOE]), particularly in people with cognitive decline (PWCD, ie, dementia and/or mild cognitive impairment). Epilepsy is associated with worse cognitive and mortality outcomes in PWCD. Identifying PWCD at risk for developing LOE can facilitate early screening and treatment of epilepsy. Objective: To investigate factors associated with LOE in PWCD. Design, Setting, and Participants: This longitudinal, multicenter study is based on participants from 39 US Alzheimer's Disease Research Centers from September 2005 through December 2021. Of 44 713 participants, 25 119 PWCD were identified. Of these, 14 685 were included who did not have epilepsy at enrollment, had 2 or more visits, and were 60 years or older at the most recent follow-up. Exposure: The association between various factors and LOE development in PWCD was investigated. Main Outcomes and Measures: The primary outcome was LOE, defined as seizures starting at or after 60 years of age. Those who did not develop LOE but were 60 years or older at follow-up served as controls. A multivariable Cox regression analysis assessed the association between various factors and LOE. Independent variables included age, sex, and socioeconomic factors (education, race, ethnicity), cardiovascular risks (hypertension, diabetes, hyperlipidemia), cerebrovascular disease (stroke or history of transient ischemic attack [TIA]), other neurologic comorbidities (Parkinson disease [PD], traumatic brain injury), cognition (age at dementia onset, dementia severity, type of dementia [Alzheimer disease (AD) versus non-AD]), genetics (apolipoprotein E4 [ APOE4 ] status), lifestyle (alcohol misuse, smoking), and depression. Results: Of the 14 685 participants (7355 female [50%] and 7330 male [50%]; mean [SD] age, 73.8 [8.5] years) who met the inclusion criteria, 221 participants (1.5%) developed LOE during follow-up. After adjusting for demographics, cardiovascular risks, neurologic comorbidities, genetics, cognitive factors, and depression, the following were associated with a higher risk of developing LOE: APOE4 allele (adjusted hazard ratio [aHR], 1.39; 95% CI, 1.04–1.86; P = .03), dementia onset before age 60 years (aHR, 2.46; 95% CI, 1.53–3.95; P < .001), worse cognition (aHR, 2.35; 95% CI, 1.97–2.79; P < .001), AD dementia subtype (aHR, 1.68; 95% CI, 1.13–2.49; P = .01), stroke/TIA (aHR, 2.03; 95% CI, 1.37–3.01; P < .001), and PD (aHR, 2.53; 95% CI, 1.08–5.95; P = .03). In sensitivity analysis, using an alternative LOE definition of epilepsy onset after age 65 years revealed the same factors associated with LOE. Conclusion and Relevance: This study showed that the APOE4 allele, dementia onset before age 60 years, AD dementia subtype, worse cognition, stroke/TIA, and PD are associated with LOE development in PWCD. PWCD with these risk factors may be considered for routine screening with an electroencephalogram for early identification of LOE.
Catheter Ablation of Ventricular Tachycardia in Histologically Confirmed, Clinically Diagnosed, and Suspected Cardiac Sarcoidosis
Prajapati, Poojan , Muthu, Padmapriya , Sorajja, Dan , Jokerst, Clinton, Rojas, Carlos A. , Masry, Hicham El , Vemulapalli, Hema Srikanth , El Masry, Hicham , Rodriguez, Juan F. , Srivathsan, Komandoor

Circulation Journal | August 9, 2025 | Volume: 90 | Issue: 1 | Pages: 99-108

10.1253/circj.cj-25-0285 | PMID 40790800 Get It

Maternal Use of Antidepressants in Pregnancy and the Risk of Postpartum Hemorrhage: An Electronic Health Record‐Based Cohort Study
Bobo, William V. , White, Launia J. , Hodge, David O. , Moore, Katherine M. , Betcher, Hannah K. , Larish, Alyssa M., Stoppel, Cynthia , Talati, Ardesheer , White, Launia, Hodge, David, Moore, Katherine, Betcher, Hannah, V Bobo, William

Human Psychopharmacology: Clinical and Experimental | August 9, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1002/hup.70015 | PMID 40782326 Get It

ABSTRACTObjectivesPrior studies have raised concerns about postpartum hemorrhage (PPH) risk associated with selective serotonin and serotonin‐norepinephrine reuptake inhibitors (SSRIs and SNRIs), although limitations include possible confounding by maternal indications. The current study examined the risk of PPH associated with prenatal S/NRIs accounting for diagnosed maternal depression during pregnancy.MethodsThe current study is a secondary analysis of data from a cohort of 2213 pregnancies (1997–2010) identified from a large electronic medical record‐linkage system. Exposures were identified from electronic prescriptions records and resulted in three main groups: S/NRI‐exposed pregnancies (S/NRI users), antidepressant‐unexposed pregnancies (non‐users), and S/NRI exposure in the year prior to (but not during) pregnancy (former users). Data used to identify PPH occurrences included obstetrician chart diagnoses, diagnosis codes, and recorded estimated blood loss (EBL). The risk of PPH by exposure group was estimated using unadjusted, minimally adjusted (maternal age at delivery, delivery year, parity, and maternal smoking), and depression‐adjusted models (previous covariates and maternal depression). Supplemental analyses included an examination of PPH risk with prenatal bupropion monotherapy.ResultsThe study cohort consisted of 837 S/NRI users, 401 former users, and 786 non‐users, as well as 114 bupropion users identified for additional analyses. The frequency of PPH was 11.6% in the overall cohort, and was 14.7% for S/NRI users, 10.2% for former users, and 8.7% for non‐users. The risk of PPH was significantly higher for S/NRI users than non‐users in unadjusted (OR 1.82 [95% CI 1.33, 2.49]), minimally adjusted (aOR 1.66 [1.19, 2.31]), and depression‐adjusted models (aOR 1.46 [1.02, 2.10]). The risk of PPH was also higher for S/NRI former users than non‐users in unadjusted models (OR 1.54 [1.05, 2.26]) but not minimally adjusted (aOR 1.42 [0.95, 2.11]) or depression‐adjusted models (aOR 1.41 [0.95, 2.10]). No significant differences in PPH risk were observed between S/NRI users and former users, between bupropion users and non‐users, or between S/NRI users and bupropion users.ConclusionsPrenatal S/NRI exposure was associated with an increased risk of PPH after adjusting for maternal depression, although residual confounding and confounding by other factors (including unmeasured factors) may be possible, as the risk of PPH appeared to be similar between S/NRI users and former users. Best‐practice PPH risk management strategies should be adhered to for depressed patients, especially those who require treatment with antidepressants during pregnancy.
Interventions in Palliative Care Compatible With Cognitive Impairment: A Systematic Review
Carozza, Sofia , Miller, Paul , Egan, Michael, Wade, Carrie G., Laenger, Jessica, Egan, Michael, Wade, Carrie G., Laenger, Jessica , Rhee, John Yohan

Review of General Psychology | August 9, 2025 | Volume: 29 | Issue: 4 | Pages: 426-441

10.1177/10892680251366541 Get It

Introduction: Patients with cognitive impairments, who may be unable to engage in traditional psychotherapies, may require support through non-cognitive interventions. This review synthesizes the existing literature to assess the evidence base for these interventions and to propose future directions for research. Methods: A comprehensive literature search was conducted across seven electronic databases on October 17, 2024. Eligible studies assessed psychological, emotional, social, or spiritual outcomes. Results: Seventy-three studies were included, conducted across 18 countries. Music therapy and art therapy had the strongest empirical support, with consistent effects on distress, emotional expression, social and spiritual connectedness, and finding meaning. Other approaches, including movement therapy, spiritual interventions, and pet therapy, showed promising but preliminary results. Aromatherapy and massage therapy yielded mixed findings, while energy-based methods lacked robust evidence. Most studies had a high risk of bias, primarily due to confounding. Few interventions were conducted with patients with cognitive impairments, despite their potential relevance. Conclusion: A variety of interventions compatible with cognitive impairment show promise in palliative care settings. However, existing empirical support is constrained by bias and a lack of research in cognitively-impaired populations.
Seminar in Epileptology: Normal awake and sleep patterns, interictal abnormalities, and ictal patterns on scalp EEG
Alcalá-Zermeño, Juan Luis , Katyal, Roohi , Frauscher, Birgit , Schomer, Donald L., Tatum, William O. , Beniczky, Sándor , Frauscher, Birgit , Sperling, Michael R. , Strowd, Roy E. , Wirrell, Elaine , Nascimento, Fábio A.

Epileptic Disorders | August 9, 2025 | Volume: 27 | Issue: 5 | Pages: 803-866

10.1002/epd2.70071 | PMID 40782030 Get It

Abstract The accurate interpretation of scalp EEG remains an instrumental diagnostic component of epilepsy care. Knowledge of what constitutes normal EEG findings, non‐epileptiform abnormalities, and epileptiform patterns—both ictal and interictal—is essential for appropriate patient management. The International League Against Epilepsy (ILAE) has developed an educational curriculum containing learning objectives necessary to accurately diagnose and manage people with epilepsy. In this Seminar in Epileptology, we address the learning objectives related to assessment and interpretation of EEG background activity, normal sleep patterns, provocation methods, interictal abnormalities, and ictal patterns, as well as a brief discussion on relevant advances in scalp EEG analysis and future perspectives on this topic.
Prevention of Calcium Hydroxyapatite Nodules in the Neck With Use of Botulinum Toxin: A Case Report and Review of Anatomy and Pathophysiology
Kang, Bianca Y. , Fabi, Sabrina G. , Hoss, Elika

Journal of Cosmetic Dermatology | August 9, 2025 | Volume: 24 | Issue: 8 | Pages: No page available

10.1111/jocd.70385 | PMID 40781936 Get It

ABSTRACTBackgroundCalcium hydroxylapatite (CaHA) is a biostimulatory filler frequently used in a hyperdilute form to improve skin quality. While generally safe, nodule formation is the most common adverse event, particularly in dynamic areas.AimsTo describe a case of delayed‐onset CaHA nodules in the neck and review anatomical and procedural factors contributing to this complication, as well as prevention and management strategies.PatientA 72‐year‐old woman underwent three sessions of hyperdilute CaHA injections to the neck, with recent or concurrent onabotulinumtoxinA injections. After the third treatment, which followed a longer interval since her last botulinum toxin injection, she developed multiple firm, non‐tender nodules. A stepwise approach with intralesional saline injections—initially using needles and later a cannula—was implemented.ResultsInitial saline injections with small‐gauge needles yielded minimal improvement. Transitioning to a 22G cannula enabled both saline delivery and mechanical disruption, resulting in complete resolution after five total treatments. The patient has remained recurrence‐free for over 2 years.ConclusionsNodule formation following CaHA injection is most often due to product aggregation, and is particularly common in dynamic areas with thin overlying skin. Combining treatment with botulinum toxin may reduce this risk by limiting movement. Other preventive strategies include using higher dilutions of CaHA, avoiding high‐risk areas, and optimizing injection depth. When nodules do occur, mechanical disruption with a cannula combined with saline injection is a safe, effective, and minimally invasive first‐line treatment.
DNA Immunotherapy ( INO ‐3107) Results in Long‐Term Surgery Reduction in RRP
Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Pransky, Seth M. , Welsh, Christopher, Slog, Stefani A., Gillespie, Elisabeth, Dallas, Michael, Morrow, Matthew P. , Skolnik, Jeffrey , Best, Simon R , Lott, David G , Mau, Ted , Paniello, Randal C , Slog, Stefani A , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Welsh, Christopher, Dallas, Michael J.

The Laryngoscope | August 9, 2025 | Volume: 135 | Issue: 11 | Pages: 4287-4295

10.1002/lary.32416 | PMID 40781903 Get It

ABSTRACT Objective To evaluate the long‐term safety and clinical effect of INO‐3107 immunotherapy in adults with recurrent respiratory papillomatosis (RRP). Methods RRP‐002 was a retrospective, observational extension study that followed patients enrolled in the 52‐week RRP‐001 study. Patients with moderate to severe juvenile or adult‐onset RRP who had undergone ≥ 2 surgical interventions in the year preceding dosing were eligible for enrollment in RRP‐001. Participants underwent surgical debulking within 14 days prior to initial dosing and then received INO‐3107 on Day 0, Weeks 3, 6, and 9. Efficacy assessments during RRP‐002 follow‐up were the frequency of surgical interventions and alternative medication use. The safety evaluation included reported serious adverse events (SAEs). Results Twenty‐eight (28) of 32 participants from the 52‐week RRP‐001 study were enrolled in RRP‐002. The median follow‐up time for RRP‐002 was 1.8 years (range: 1.2–2.4 years) for a total median assessment time of 2.8 years (range: 1.0–3.5 years). There were no SAEs or long‐term safety concerns identified. The mean number of surgeries was reduced from 4.1 in the pre‐treatment period to 1.7 in the first year post‐INO‐3107 treatment (Year 1) to 0.9 in the second year (Year 2). The complete response rate (0 surgeries per year) increased from 28% (9/32) in Year 1 to 50% (14/28) in Year 2. Conclusion INO‐3107 is well tolerated and provides a continued clinical effect against HPV‐6 and 11 RRP that results in further reduction of the surgical burden observed in Year 1. These data support the role of INO‐3107 immunotherapy for adult patients with RRP. Level of Evidence: III.